Funding search · EIN 263160079 · Austin, TX

Foundation for Angelman Syndrome

Name: Foundation for Angelman Syndrome grants, 2022–2024
Creator: PaperOrbit
License: https://www.irs.gov/charities-non-profits/exempt-organization-public-disclosure-and-availability-requirements

A grantmaking public charity (files IRS Form 990, Schedule I). Charities like this often run real grant programs with application cycles.

31
grants reported: $14.3M
total given: 2022–2024
filing years: $194,000
median grant

Based on grants this organization reported to the IRS for tax years 2022–2024. This is what they filed, not a complete record of their giving, and recent years may be incomplete because filings lag.

Funder website ↗Full IRS filings ↗How this is built Report an error

Funding pattern

What this funder pays for, at what size, and how to position adjacent work. Read from their filings, with every number checked against the record.

8 grants matching “Down syndrome” · $1.4M

$274,044
Regents of the University of California Davis · Davis, CA · 2024
Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome
$210,711
The Regents of the University of California San Francisco · San Francisco, CA · 2024
Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome
$140,846
Children'S Research Institute · Washington, DC · 2024
Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome
$125,000
Keck Graduate Institute of Applied Life Sciences · Claremont, CA · 2024
Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides
$250,000
Keck Graduate Institute of Applied Life Sciences · Claremont, CA · 2023
Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides
$246,600
Children'S Research Institute · Washington, DC · 2023
Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome
$93,702
The Regents of the University of California San Francisco · San Francisco, CA · 2023
Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome
$75,000
Regents of the University of California Davis · Davis, CA · 2023
Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome

Grant history

All 31 reported grants, largest first.

$5.9M
University of Pennsylvania · Philadelphia, PA · 2024
Upenn 2023: research, collaboration & license agreement
$1.9M
University of Pennsylvania · Philadelphia, PA · 2023
Upenn 2023: research, collaboration & license agreement
$1.3M
Rush University Medical Center · Chicago, IL · 2023
Rush coe
$470,957
Boston Children'S Hospital · Boston, MA · 2024
Ft2022-006: abom - natural history study
$458,118
Boston Children'S Hospital · Boston, MA · 2023
Ft2022-006: abom - natural history study
$320,500
Rush University Medical Center · Chicago, IL · 2024
Rush coe
$317,848
Duke University · Charlotte, NC · 2024
Ft2018-005 amended: gpic-comm
$277,778
Texas a&M University · College Station, TX · 2022
Translational research in pig model of as
$274,044
Regents of the University of California Davis · Davis, CA · 2024
Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome
$267,142
Texas a&M University · College Station, TX · 2023
Ft2019-008: translational research in pig model of as
$257,475
Yale University · New Haven, CT · 2023
Ft2020-006: generation and characterization of a new as mouse model that recapitulates the large deletion of human 15q11-q13 and a control line that carries a deletion of all genes in 15q11-q13 but ube3a
$250,000
Keck Graduate Institute of Applied Life Sciences · Claremont, CA · 2023
Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides
$246,600
Children'S Research Institute · Washington, DC · 2023
Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome
$233,299
Yale University · New Haven, CT · 2022
Generation and characterization of a new as mouse model that recapitulates the large deletion of human 15q11-q13 and a control line that carries a deletion of all genes in 15q11-q13 but ube3a
$210,711
The Regents of the University of California San Francisco · San Francisco, CA · 2024
Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome
$194,000
Brown University · Providence, RI · 2023
Ft2022-005: development of bdnf potentiating therapeutics for motor and cognitive dysfunction in as
$178,887
North Carolina State University · Raleigh, NC · 2023
Ft2022-001: microprobe-integrated human organoid arrays to study as genotypes and therapeutics
$173,873
North Carolina State University · Raleigh, NC · 2022
Bandodkar lab human organoid arrays to study as
$161,647
North Carolina State University · Raleigh, NC · 2023
Ft2021-002: isogenically controlled human cell lines targeting aberrant imprinting genotypes and a new reporter cell line.
$150,000
Brown University · Providence, RI · 2024
Ft2022-005: development of bdnf potentiating therapeutics for motor and cognitive dysfunction in as
$140,846
Children'S Research Institute · Washington, DC · 2024
Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome
$125,000
Keck Graduate Institute of Applied Life Sciences · Claremont, CA · 2024
Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides
$115,121
University of Pennsylvania · Philadelphia, PA · 2022
A. The ube3a antisense transcript (ube3a-as) is a long non-coding mrna that silences expression of the paternal ube3a gene in neurons. Interruption of this imprinting phenomenon can be done through asos, crispr-grna or … read allA. The ube3a antisense transcript (ube3a-as) is a long non-coding mrna that silences expression of the paternal ube3a gene in neurons. Interruption of this imprinting phenomenon can be done through asos, crispr-grna or other technologies like microrna (mirna). This project is aiming to develop a strategy to suppress the ube3a-as in the mouse model of as using mirnas. Advantages to mirna are that they are subject to endogenous cellular processing and regulation, which can help circumvent issues related to overexpression of exogenous genetic material (with ube3a replacement), and the need for repeated redosing (with asos). Mirna is thought to be advantageous over shrna due to endogenous cellular processing and regulation compared to overexpression you could get with shrna. less
$93,702
The Regents of the University of California San Francisco · San Francisco, CA · 2023
Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome
$75,445
Duke University · Charlotte, NC · 2023
Ft2018-005 amended: gpic-comm
$75,000
Regents of the University of California Davis · Davis, CA · 2023
Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome
$50,500
Brown University · Providence, RI · 2024
Pd2023-001: postdoctoral fellowship program
$50,500
Brown University · Providence, RI · 2023
Pd2023-001: postdoctoral fellowship program
$50,500
Yale University · New Haven, CT · 2023
Pd2022-001: postdoctoral fellowship program
$43,087
North Carolina State University · Raleigh, NC · 2023
Ft2022-008: stem cell line in-vitro infrastructure created at ncsu for industry and academic support
$29,315
North Carolina State University · Raleigh, NC · 2023
Radar 2023-2137

Who else funds this kind of work

Same state

Greater Houston Community Foundation5,612 grants · $873.8M
The Big 12 Conference50 grants · $1.91B
Texas Essential Healthcare Partnerships297 grants · $972.3M

Similar grant size

The Ford Foundation10,731 grants · $2.35B
John D and Catherine T MacArthur Foundation (Consolidated)7,100 grants · $1.67B
Wk Kellogg Foundation7,234 grants · $1.30B

Grants already paid are the record; PaperOrbit reads your paper and finds the funders whose record matches it — then explains why.

Search funders like this one

Source: IRS Form 990, Schedule I, as filed by this organization. These are grants already paid. Grants paid directly to individuals are reported to the IRS only as totals, so they do not appear as named lines here.